EXACT Sciences Co. (EXAS) Expected to Announce Earnings of -$0.39 Per Share

Brokerages expect EXACT Sciences Co. (NASDAQ:EXAS) to report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for EXACT Sciences’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.38). EXACT Sciences posted earnings per share of ($0.32) during the same quarter last year, which would indicate a negative year over year growth rate of 21.9%. The company is scheduled to report its next earnings report on Thursday, April 26th.

On average, analysts expect that EXACT Sciences will report full-year earnings of ($0.92) per share for the current financial year, with EPS estimates ranging from ($1.02) to ($0.78). For the next fiscal year, analysts expect that the company will report earnings of ($0.04) per share, with EPS estimates ranging from ($0.24) to $0.21. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that follow EXACT Sciences.

How to Become a New Pot Stock Millionaire

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Thursday, February 22nd. The medical research company reported ($0.18) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.09. The firm had revenue of $87.41 million during the quarter, compared to analyst estimates of $87.42 million. EXACT Sciences had a negative return on equity of 24.13% and a negative net margin of 43.01%. The company’s revenue was up 148.0% on a year-over-year basis. During the same period last year, the company earned ($0.34) earnings per share.

EXAS has been the subject of a number of research reports. Leerink Swann set a $67.00 price objective on EXACT Sciences and gave the stock a “buy” rating in a research report on Friday, February 23rd. BidaskClub lowered EXACT Sciences from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 23rd. Benchmark set a $65.00 price objective on EXACT Sciences and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a research report on Tuesday, January 16th. Finally, William Blair restated a “buy” rating on shares of EXACT Sciences in a report on Wednesday, January 10th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $52.84.

In other news, SVP D Scott Coward sold 2,122 shares of EXACT Sciences stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $40.12, for a total transaction of $85,134.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Maneesh Arora sold 5,295 shares of EXACT Sciences stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $52.19, for a total value of $276,346.05. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 449,995 shares of company stock worth $21,876,323. Company insiders own 4.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the company. C M Bidwell & Associates Ltd. bought a new position in shares of EXACT Sciences during the 4th quarter valued at about $117,000. Crow Point Partners LLC bought a new position in shares of EXACT Sciences during the 4th quarter valued at about $145,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of EXACT Sciences by 2,925.7% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 3,177 shares of the medical research company’s stock valued at $150,000 after purchasing an additional 3,072 shares in the last quarter. Advisory Services Network LLC lifted its holdings in shares of EXACT Sciences by 6,600.0% during the 4th quarter. Advisory Services Network LLC now owns 3,350 shares of the medical research company’s stock valued at $176,000 after purchasing an additional 3,300 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of EXACT Sciences during the 3rd quarter valued at about $183,000. Institutional investors and hedge funds own 82.02% of the company’s stock.

EXAS stock traded down $2.66 during midday trading on Friday, reaching $37.84. The stock had a trading volume of 2,043,048 shares, compared to its average volume of 2,268,270. The company has a quick ratio of 6.77, a current ratio of 7.15 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4,898.13, a price-to-earnings ratio of -38.22 and a beta of 0.87. EXACT Sciences has a twelve month low of $22.30 and a twelve month high of $63.60.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3339082/exact-sciences-co-exas-expected-to-announce-earnings-of-0-39-per-share.html.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Get a free copy of the Zacks research report on EXACT Sciences (EXAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jane Street Group LLC Purchases New Holdings in Quality Care Properties Inc
Jane Street Group LLC Purchases New Holdings in Quality Care Properties Inc
Ironvine Capital Partners LLC Purchases New Position in Oracle Co.
Ironvine Capital Partners LLC Purchases New Position in Oracle Co.
Jane Street Group LLC Sells 16,407 Shares of ProShares UltraShort Technology
Jane Street Group LLC Sells 16,407 Shares of ProShares UltraShort Technology
Celgene  Shares Sold by HighPoint Advisor Group LLC
Celgene Shares Sold by HighPoint Advisor Group LLC
Mplx  Lifted to “Buy” at Guggenheim
Mplx Lifted to “Buy” at Guggenheim
Morgan Stanley Increases Exelon  Price Target to $43.00
Morgan Stanley Increases Exelon Price Target to $43.00


Leave a Reply

© 2006-2018 Ticker Report. Google+.